{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T19:46:08Z","timestamp":1792352768369,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T00:00:00Z","timestamp":1329350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s11894-012-0249-5","type":"journal-article","created":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T06:58:46Z","timestamp":1329289126000},"page":"166-173","source":"Crossref","is-referenced-by-count":10,"title":["Medical Therapy for Pediatric Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"14","author":[{"given":"Mary E.","family":"Sherlock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,16]]},"reference":[{"key":"249_CR1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ibd.21349","volume":"17","author":"E Benchimol","year":"2011","unstructured":"Benchimol E, Fortinsky K, van der Heuvel M, van Limbergen J, Griffiths AM. Epidemiology of pediatric IBD: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423\u201339.","journal-title":"Inflamm Bowel Dis"},{"key":"249_CR2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MPG.0b013e318218be35","volume":"53","author":"C Braegger","year":"2011","unstructured":"Braegger C, Balabbeni P, Rogler D, et al. Epidemiology of inflammatory bowel disease: is there a shift towards onset at an earlier age? J Pediatr Gastro Nutr. 2011;53:141\u20134.","journal-title":"J Pediatr Gastro Nutr"},{"key":"249_CR3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/ng.489","volume":"41","author":"M Imielinski","year":"2009","unstructured":"Imielinski M, Baldassano R, Griffiths AM, et al. Common variants at 16p11 implicate IL-27 in childhood-onset inflammatory bowel disease. Nat Genet. 2009;41:1335\u201340.","journal-title":"Nat Genet"},{"key":"249_CR4","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","volume":"361","author":"EO Glocker","year":"2009","unstructured":"\u2022\u2022 Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033\u201345. A landmark paper which breaks new ground in infantile-onset multi-system inflammatory disorders that include intestinal inflammation and even perianal disease, but also stimulates research into the role of the IL-10 pathway in complex IBD.","journal-title":"N Engl J Med"},{"key":"249_CR5","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","volume":"17","author":"A Levine","year":"2011","unstructured":"\u2022 Levine A, Griffiths AM, Markowitz J, et al. Pediatric Modification of the Montreal Classification for Inflammatory Bowel Disease - the Paris Classification. Infl Bowel Dis Inflamm Bowel Dis. 2011;17:1314\u201321. A critical attempt to define important phenotypic characteristics of pediatric onset IBD.","journal-title":"Infl Bowel Dis Inflamm Bowel Dis."},{"issue":"4","key":"249_CR6","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","volume":"135","author":"J Limbergen Van","year":"2008","unstructured":"\u2022\u2022 Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135(4):1114\u201322. A careful prospective analysis of the clinical evolution of pediatric IBD in comparison to adult onset IBD diagnosed in Scotland.","journal-title":"Gastroenterology"},{"issue":"4","key":"249_CR7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/j.gastro.2008.06.079","volume":"135","author":"G Vernier-Massouille","year":"2008","unstructured":"\u2022\u2022 Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn\u2019s disease: a population-based cohort study. Gastroenterology. 2008;135(4):1106\u201313. Appearing at the same time, an examination of the phenotypic evolution of pediatric IBD in a population-based French cohort.","journal-title":"Gastroenterology"},{"key":"249_CR8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrgastro.2009.124","volume":"6","author":"TD Walters","year":"2009","unstructured":"\u2022 Walters TD, Griffiths AM. Mechanisms of Disease: growth impairment in paediatric Crohn\u2019s disease. Nature Rev Gastroenterol Hepatol. 2009;6:513\u201323. A comprehensive review of pathogenetic mechanisms of growth impairment in pediatric CD.","journal-title":"Nature Rev Gastroenterol Hepatol"},{"key":"249_CR9","doi-asserted-by":"crossref","unstructured":"\u2022 Wilson D, Thomas A, Croft N, et al. Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2010 Jan 13. A comprehensive magnum opus, which recognizes the paucity of randomized controlled trials in children.","DOI":"10.1097\/MPG.0b013e3181c92caa"},{"issue":"3","key":"249_CR10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bpg.2004.01.002","volume":"18","author":"AM Griffiths","year":"2004","unstructured":"Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18(3):509\u201323.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"249_CR11","doi-asserted-by":"crossref","unstructured":"Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2008 Jul 16;(3)(3):CD000296.","DOI":"10.1002\/14651858.CD000296.pub3"},{"key":"249_CR12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ibd.20881","volume":"15","author":"A Levine","year":"2009","unstructured":"Levine A. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn\u2019s disease: A randomized placebo-controlled trial. Inflamm Bowel Dis. 2009;15:1055\u201361.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"249_CR13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2036.2009.04067.x","volume":"30","author":"E Buchanan","year":"2009","unstructured":"Buchanan E, Gaunt WW, Cardigan T, et al. The use of exclusive enteral nutrition for induction of remission in children with Crohn\u2019s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30(5):501\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"249_CR14","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cgh.2006.03.010","volume":"4","author":"O Borrelli","year":"2006","unstructured":"Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn\u2019s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4(6):744\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"249_CR15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2036.2007.03578.x","volume":"27","author":"AS Day","year":"2008","unstructured":"Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy in paediatric Crohn\u2019s disease. Aliment Pharmacol Ther. 2008;27(4):293\u2013307.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"249_CR16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2036.2008.03796.x","volume":"28","author":"ST Leach","year":"2008","unstructured":"\u2022 Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn\u2019s disease. Aliment Pharmacol Ther. 2008;28(6):724\u201333. An interesting attempt to investigate the mechanism of action of enteral nutrition as primary therapy.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"249_CR17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology. 2007;132(3):863\u201373.","journal-title":"Gastroenterology"},{"key":"249_CR18","doi-asserted-by":"crossref","unstructured":"\u2022 Hyams J, Griffiths AM, Markowitz J et al Induction and Maintenance Adalimumab for Moderate to Severe Crohn\u2019s Disease in Children: A Randomized Double-Blind Trial. Gastroenterology 2011;140:S90. A large multi-center trial by pediatric standards, with nice stratification of patients according to prior anti-TNF exposure.","DOI":"10.1016\/S0016-5085(11)60369-7"},{"key":"249_CR19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(02)08465-9","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomized trial. Lancet. 2002;359:1451\u20139.","journal-title":"Lancet"},{"issue":"3","key":"249_CR20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357(3):228\u201338.","journal-title":"N Engl J Med"},{"key":"249_CR21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.dld.2003.12.014","volume":"36","author":"O Borelli","year":"2004","unstructured":"Borelli O, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn\u2019s disease. Dig Liver Dis. 2004;36:342\u20137.","journal-title":"Dig Liver Dis"},{"issue":"12","key":"249_CR22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829\u201338.","journal-title":"Ann Intern Med"},{"key":"249_CR23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens G, et al. Early combined immunesuppression or conventional management in recently diagnosed patients with Crohn\u2019s disease: an open randomized trial. Lancet. 2008;371:660\u20137.","journal-title":"Lancet"},{"key":"249_CR24","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1365-2036.2008.03835.x","volume":"28","author":"T Sipponen","year":"2008","unstructured":"Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn\u2019s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"249_CR25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/gast.2000.18144","volume":"119","author":"J Markowitz","year":"2000","unstructured":"Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn\u2019s disease. Gastroenterology. 2000;119(4):895\u2013902.","journal-title":"Gastroenterology"},{"issue":"12","key":"249_CR26","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1111\/j.1572-0241.2007.01474.x","volume":"102","author":"D Turner","year":"2007","unstructured":"Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn\u2019s disease. Am J Gastroenterol. 2007;102(12):2804\u201312.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"249_CR27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/01.mib.0000235103.47280.bb","volume":"12","author":"S Uhlen","year":"2006","unstructured":"Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn\u2019s disease: a French multicenter study. Inflamm Bowel Dis. 2006;12(11):1053\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"249_CR28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","volume":"4","author":"EA Maser","year":"2006","unstructured":"Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248\u201354.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"15","key":"249_CR29","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"\u2022\u2022 Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362(15):1383\u201395. Conducted in adult patients, but addressing what has been a major question about optimal treatment regimens with infliximab therapy (mono- versus combination). Also provides prospective data on mucosal healing rates with azathioprine and with infliximab and with combination therapy.","journal-title":"N Engl J Med"},{"key":"249_CR30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","volume":"58","author":"F Schnitzler","year":"2009","unstructured":"\u2022 Schnitzler F, et al. Longterm outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort. Gut. 2009;58:492\u20138. Excellent single-center account of real-world experience in adults. Similar is needed in pediatrics!.","journal-title":"Gut"},{"key":"249_CR31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ibd.20329","volume":"14","author":"L deRidder","year":"2008","unstructured":"deRidder L, et al. Infliximab Dependency in Pediatric Crohn\u2019s Disease: Longterm follow-up of an Unselected Cohort. Inflamm Bowel Dis. 2008;14:353\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"249_CR32","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/gut.2008.163279","volume":"57","author":"M Shale","year":"2008","unstructured":"\u2022 Shale M, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639\u201341. Excellent summary and analysis.","journal-title":"Gut"},{"issue":"8","key":"249_CR33","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","volume":"13","author":"JR Rosh","year":"2007","unstructured":"Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn\u2019s disease: a cautionary tale. Inflamm Bowel Dis. 2007;13(8):1024\u201330.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"249_CR34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","volume":"9","author":"DS Kotlyar","year":"2011","unstructured":"\u2022 Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36\u201341.e1. Another up to date summary and analysis.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"249_CR35","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cgh.2010.04.023","volume":"8","author":"G Melmud","year":"2010","unstructured":"Melmud G, et al. The appropriateness of concomitant immunemodulators with anti-TNF agents for Crohn\u2019s disease: one size does not fit all. Clin Gastro Hepatol. 2010;8:655.","journal-title":"Clin Gastro Hepatol"},{"key":"249_CR36","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552\u201363.","journal-title":"Arthritis Rheum"},{"key":"249_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.20075","volume":"13","author":"TD Walters","year":"2007","unstructured":"Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn disease. Inflamm Bowel Dis. 2007;13:1\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"249_CR38","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2036.2011.04603.x","volume":"33","author":"RK Russell","year":"2011","unstructured":"Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(8):946\u201353.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"249_CR39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","volume":"133","author":"D Turner","year":"2007","unstructured":"Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423\u201332.","journal-title":"Gastroenterology"},{"key":"249_CR40","unstructured":"Zeisler B, Lerer T, Markowitz J et al. Outcome following aminosalicylate therapy in children newly diagnosed with ulcerative colitis: a prospective multi-center registry experience."},{"issue":"9","key":"249_CR41","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cgh.2006.04.008","volume":"4","author":"J Hyams","year":"2006","unstructured":"Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastro Hepatol. 2006;4(9):1118\u201323.","journal-title":"Clin Gastro Hepatol"},{"key":"249_CR42","doi-asserted-by":"crossref","unstructured":"Hyams J, Damaraju L, Blank M et al. A randomized multi-center open label phase 3 study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate to severe ulcerative colitis. Clin Gastro Hepatol 2011. doi: 10.1016\/j.cgh.2011.11.026 .","DOI":"10.1016\/j.cgh.2011.11.026"},{"issue":"2","key":"249_CR43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ajg.2008.118","volume":"104","author":"E Miele","year":"2009","unstructured":"Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104(2):437\u201343.","journal-title":"Am J Gastroenterol"},{"key":"249_CR44","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ajg.2010.493","volume":"5","author":"JS Hyams","year":"2011","unstructured":"Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011;5:981\u20137.","journal-title":"Am J Gastroenterol"},{"key":"249_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.2007.136481","volume":"57","author":"D Turner","year":"2008","unstructured":"Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes, and optimal timing for second line therapy. Gut. 2008;57:1\u201310.","journal-title":"Gut"},{"key":"249_CR46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ibd.21383","volume":"17","author":"D Turner","year":"2011","unstructured":"Turner D, Griffiths A. Acute severe paediatric ulcerative colitis: a systematic review. Inflamm Bowel Dis. 2011;17:440\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"249_CR47","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1053\/j.gastro.2010.02.047","volume":"138","author":"D Turner","year":"2010","unstructured":"\u2022 Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138(7):2282\u201391. The first sizeable prospective assessment of intravenous corticosteroid therapy for acute severe pediatric ulcerative colitis.","journal-title":"Gastroenterology"},{"key":"249_CR48","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ajg.2010.481","volume":"106","author":"D Turner","year":"2011","unstructured":"\u2022 Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastro. 2011;106:574\u201388. A useful guide to management of this severe cohort of patients.","journal-title":"Am J Gastro"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-012-0249-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-012-0249-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-012-0249-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T19:14:06Z","timestamp":1713554046000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-012-0249-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,16]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1007\/s11894-012-0249-5","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,16]]}}}